Nucala is Now Approved For 4 Rare Eosinophil-Based Diseases in Europe

GlaxoSmithKline has recently announced their new approval of Nucala by the European Commission. This therapy has been approved for three new diseases, all of which are driven by eosinophils. Nucala is…

Continue Reading Nucala is Now Approved For 4 Rare Eosinophil-Based Diseases in Europe
Nucala Recommended for Three New Indications
stevepb / Pixabay

Nucala Recommended for Three New Indications

Nucala has already been approved in Europe as an add-on treatment for patients with extreme eosinophilic asthma. Now, the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended…

Continue Reading Nucala Recommended for Three New Indications

Editor’s Choice: Can Machine Learning Help Rare Patients Get Diagnosed and Treated Faster?

Happy Friday! October is Dysautonomia Awareness Month. Dysautonomia is a collection of conditions that affect the autonomic nervous system. This can lead to a loss of control of the body's…

Continue Reading Editor’s Choice: Can Machine Learning Help Rare Patients Get Diagnosed and Treated Faster?
Nucala Granted Priority Review For Treatment of Hypereosinophilic Syndrome
PhotoLizM / Pixabay

Nucala Granted Priority Review For Treatment of Hypereosinophilic Syndrome

  According to a drug filing and press release from Pharmaceutical Business Review, the FDA granted a priority review to GlaxoSmithKline for their humanized monoclonal antibody therapy, Nucala (mepolizumab). Currently,…

Continue Reading Nucala Granted Priority Review For Treatment of Hypereosinophilic Syndrome
Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11
Source: Pixabay

Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11

According to a press release from global pharmaceuticals titan GlaxoSmithKline, the US Food and Drug Administration (FDA) recently expanded approval of the Company's eosinophilic asthma treatment Nucala (generic name mepolizumab)…

Continue Reading Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11

Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Hypereosinophilic Syndrome Hypereosinophilic syndrome (HES) is a rare disease which causes high levels of white blood cells in the body. These cells are called eosinophils, and they're essential for proper…

Continue Reading Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Orphan Drug Designation Granted to Potential New Hypereosinophilic Syndrome Treatment

Hypereosinophilic syndrome Hypereosinophilic syndrome (HES) refers to a group of rare conditions characterized by high levels of eosinophils which result in organ damage. These eosinophils often affect the lungs, heart, skin,…

Continue Reading Orphan Drug Designation Granted to Potential New Hypereosinophilic Syndrome Treatment
A Hypereosinophilic Syndrome Inspiration: Read This Woman’s Story
https://pixabay.com/en/workout-girl-weights-fitness-1420741/

A Hypereosinophilic Syndrome Inspiration: Read This Woman’s Story

Not only does Pamela Looney have hypereosinophilic syndrome (HES), she also has asthma and has suffered from a tumor. At only 15, the sudden development of this tumor severely affected…

Continue Reading A Hypereosinophilic Syndrome Inspiration: Read This Woman’s Story